A randomized controlled trial that included more than 300 people diagnosed with chronic spontaneous urticaria (CSU), or hives, found that acupuncture may offer limited relief from the condition, but clinical significance of this finding was unclear.
Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.